{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"72"}]}],"title":"WBC (n=299, 303)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"167"},{"groupId":"OG001","value":"164"}]}],"title":"Platelets(n=299, 303)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"142"}]}],"title":"ANC (n=299, 303)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"299"},{"groupId":"OG001","value":"303"}],"units":"Participants"}],"description":"Laboratory abnormalities were graded according to the National Cancer Institute Common Terminology Criteria (NCI CTC) Version 3.0. Grade 4 hematology evaluations used to determine myelosuppression included: WBC: \\<1.0\\*10\\^9/L. ANC: \\<0.5\\*10\\^9/L. Platelet count \\<25.0 to 10\\^9/L.","groups":[{"description":"Dasatinib was administered orally at a dose of 140 mg once a day (QD) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant.","id":"OG000","title":"Dasatinib 140 mg QD"},{"description":"Dasatinib was administered orally at a dose of 70 mg twice a day (BID) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant.","id":"OG001","title":"Dasatinib 70 mg BID"}],"paramType":"NUMBER","populationDescription":"All participants who received at least one dose of study drug and had laboratory evaluations available were analyzed. Participants were analyzed based on the treatment they actually received, not what they were randomized to receive.","reportingStatus":"POSTED","timeFrame":"Day 1 up to Year 7","title":"Number of Participants With Grade 4 Myelosuppression Determined From Hematology Evaluations","type":"SECONDARY","unitOfMeasure":"participants"}